Sutro Biopharma Inc（STRO）の財務STROSutro Biopharma Inc

Evaluating the bottom line, Sutro Biopharma Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -301.73%, while the net margin is -391.64%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively STRO converts its operational activities into shareholder value.

In the context of the broader market, STRO competes directly with industry leaders such as PDSB and MGNX. With a market capitalization of $151.96M, it holds a leading position in the sector. When comparing efficiency, STRO's gross margin of 100.00% stands against PDSB's N/A and MGNX's 100.00%. Such benchmarking helps identify whether Sutro Biopharma Inc is trading at a premium or discount relative to its financial performance.

Sutro Biopharma reported a significant revenue drop to $9.8 million in Q2 2026 from $63.7 million in Q2 2025, with a net loss of $38.5 million, highlighting ongoing financial challenges despite a strong gross margin of 100%.